ATLANTA, GA – March 3, 2017 –Wayne H. Elowe, Chair of the Atlanta office Corporate and Securities Practice at global law firm Greenberg Traurig, LLP, and co-Leader of its Biotech and Pharmaceutical team, led the Greenberg Traurig team representing Biotest AG in the sale of its US therapy business. Greenberg Traurig Shareholders Stacey Orr Gallant and Gerald L. Baxter also were key members of the transaction team.
Biotest AG recently announced that it had agreed to a deal to sell major assets from its U.S. subsidiary Biotest Pharmaceuticals Corporation (BPC) to ADMA Biologics, Inc. The deal, which is expected to close later this year, will involve the sale by BPC of certain assets of its US therapy business, according to an ADMA Biologics press release, found at this link: http://bit.ly/2jkWvFm
Biotest Pharmaceuticals Corporation is a wholly owned subsidiary of Biotest AG, a German global provider of plasma products.
Elowe concentrates his practice on international business and complex commercial transactions, with an emphasis on mergers and acquisitions, joint ventures, strategic alliances, licensing, and technology transactions. He regularly represents life sciences companies in connection with structuring and negotiating complex relationships involving the acquisition, licensing, sharing, development and monetization of various technology-driven assets and platforms. Elowe has represented clients in more than 50 countries in North America Asia, Europe, the Middle East and Latin America. In addition, he also serves in the role of outside general counsel to a number of multinational clients and is actively involved with their senior executive teams in developing and implementing strategy-concerning matters such as new business and product initiatives as well as corporate matters and litigation.
Gallant concentrates her practice in corporate law, mergers and acquisitions, debt and equity financings, and venture capital. She advises clients in complex financing transactions and represents both sellers and buyers in the structuring and negotiation of mergers, acquisitions and divestitures.
Baxter focuses his practice on corporate and securities matters in a variety of industries, including financial services, real estate, high technology and health care. He has been lead counsel in numerous public offerings, venture capital, finance and acquisitions, and divestiture transactions.
About Greenberg Traurig's Corporate & Securities Practice
Greenberg Traurig’s Corporate & Securities Practice comprises more than 400 lawyers who advise public and privately held companies and investment funds on global mergers and acquisitions, corporate restructurings, private equity and venture capital, underwritten and syndicated offerings, commercial finance and syndicated lending, cross-border transactions, and general corporate matters. The group’s industry experience includes transactions in a wide range of fields, from the pharmaceutical, medical devices, and life sciences fields, to representations involving clients in the aviation, banking, energy, health care, manufacturing, technology, and telecommunications sectors.
About Greenberg Traurig’s Life Sciences & Medical Technology Group
Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.
About Greenberg Traurig, LLP
Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. One firm worldwide, GTLaw has been recognized for its philanthropic giving, was named the second largest firm in the U.S. by Law360 in 2016, and among the Top 20 on the 2016 Am Law Global 100. Web: www.gtlaw.com Twitter: @GT_Law.